Lab Groups’ LDT Comments Will Highlight Barriers To Test Accessibility-thegraysheet: Clinical laboratory groups plan to focus their comments on FDA’s proposed regulatory framework for laboratory developed tests on the barriers to test access they say the new scheme will create. Representatives of some lab groups told “The Gray Sheet” in early August that they have already started to address FDA’s concerns about the clinical validity of the tests.
